Author

E. Nee

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Bakayoko· 1 shared A. D'Alessandro· 1 shared A. Filer· 1 shared A. Jainarayanan· 1 shared A. Jonsson· 1 shared A. Matthews· 1 shared A. Salimov· 1 shared A. Wagner· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Bakayoko

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Chemoresistance of TP53 mutant AML requires the mevalonate byproduct, GGPP, for regulation of ROS and induction of a mitochondria stress response

S. J. Skuli, A. Bakayoko, M. Kruidenier, B. Manning, P. Pammer, A. Salimov, O. Riley, G. Brake-Silla, M. Bowman, L. N. Martinez-Gutierrez, R. Buono, M. Paul, E. Saland, S. Wong, J. Xu, , M. Carroll

This study identifies GGPP, a mevalonate pathway byproduct, as critical for chemoresistance in TP53mut AML through ROS regulation and mitochondria stress response, suggesting statin-based therapies could be effective.

bioRxiv · Jun 7, 2024 · PreprintCancer Biology

A longitudinal single-cell therapeutic atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease

T. Thomas, C. Rich-Griffin, M. Pohin, M. Friedrich, D. Aschenbrenner, J. Pakpoor, A. Jainarayanan, A.-I. Voda, R. Sanches Peres, E. Nee, D. Sathananthan, D. Kotliar, J. Turner, S. Nayar, F. Zhang, , C. Buckley

This study creates a therapeutic atlas of anti-TNF treatment in IBD, showing disease- and therapy-specific cellular changes and identifying IFN signalling as a potential target for JAK inhibition.

bioRxiv · May 5, 2023Immunology